3 Stocks Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 3 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
GE HealthCare Technologies Inc., GEHC
Summary: Chicago, IL-based GE Healthcare is a leading maker of medical imaging and patient-monitoring products and related equipment and services. Approximately half of GE Healthcare's revenue comes from equipment sales, with consumables and services accounting for the other half. GE Healthcare started operating as an independent company after its January 2023 spin-off from General Electric (GE).
- Last Price: $77.83
- Price Change: $-0.43, -0.55%
- Yearly Gain: -2.36%
- Market Cap: $35.44B
- P/E Ratio: 22.63
Here are 3rd party ratings for GEHC:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Bottom 42% (146 out of 251)
What is the sentiment on the street regarding GE HealthCare Technologies Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in GEHC or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on GEHC before you decide to make any investment.
Click here for chart >>
Neurocrine Biosciences, Inc., NBIX
Summary: Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
- Last Price: $139.83
- Price Change: $-3.20, -2.24%
- Yearly Gain: 41.79%
- Market Cap: $13.91B
- P/E Ratio: 56.61
Here are 3rd party ratings for NBIX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 43% (143 out of 251)
What is the sentiment on the street regarding Neurocrine Biosciences, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in NBIX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on NBIX before you decide to make any investment.
Click here for chart >>
AtriCure, Inc., ATRC
Summary: AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart.
- Last Price: $22.22
- Price Change: $-2.54, -10.26%
- Yearly Gain: -54.02%
- Market Cap: $1.07B
- P/E Ratio: -33.67
Here are 3rd party ratings for ATRC:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 38% (156 out of 251)
What is the sentiment on the street regarding AtriCure, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Selling
- Investor Sentiment: Negative
- Hedge Fund signal: Medium Risk
If you are interested in ATRC or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ATRC before you decide to make any investment.
Click here for chart >>
Thanks for reading!